Swedbank AB Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Swedbank AB grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 722,243 shares of the medical equipment provider's stock after purchasing an additional 125,843 shares during the period. Swedbank AB owned approximately 1.04% of Lantheus worth $79,266,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC boosted its position in Lantheus by 0.4% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock valued at $1,834,000 after acquiring an additional 100 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. GAMMA Investing LLC grew its stake in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after purchasing an additional 146 shares during the period. Moody National Bank Trust Division lifted its position in Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock valued at $1,203,000 after buying an additional 162 shares during the period. Finally, NBC Securities Inc. boosted its holdings in shares of Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock valued at $53,000 after buying an additional 191 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LNTH shares. Truist Financial lowered their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Leerink Partners upped their price target on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Finally, B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $126.00.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 10,481 shares of the firm's stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the transaction, the director now owns 454,923 shares of the company's stock, valued at $43,445,146.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the business's stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,981 shares of company stock valued at $2,689,156. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

NASDAQ:LNTH traded up $0.54 on Wednesday, hitting $112.50. The stock had a trading volume of 643,811 shares, compared to its average volume of 976,882. The business's 50-day simple moving average is $104.71 and its two-hundred day simple moving average is $90.20. The stock has a market cap of $7.80 billion, a price-to-earnings ratio of 17.18 and a beta of 0.50. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. During the same period in the previous year, the business posted $1.40 EPS. The business's quarterly revenue was up 22.5% compared to the same quarter last year. As a group, research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.